HOE901-U300 (new formulation of insulin glargine)

DRUG4 trials

Sponsors

Sanofi

Conditions

Type 1 Diabetes MellitusType 2 Diabetes Mellitus

Phase 2

Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 1 Diabetes Mellitus on Basal Plus Mealtime Insulin

CompletedNCT01658579

SanofiType 1 Diabetes Mellitus

Start: 2012-08-31End: 2013-05-31Updated: 2015-06-01

Phase 3

Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Basal Insulin With Oral Antidiabetic Therapy

CompletedNCT01499095

SanofiType 2 Diabetes Mellitus

Start: 2011-12-31End: 2013-11-30Updated: 2022-03-23

Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes Mellitus on Basal Plus Mealtime Insulin

CompletedNCT01499082

SanofiType 2 Diabetes Mellitus

Start: 2011-12-31End: 2013-09-30Updated: 2022-03-25

Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Non-insulin Antidiabetic Therapy

CompletedNCT01676220

SanofiType 2 Diabetes Mellitus

Start: 2012-08-31End: 2014-03-31Updated: 2015-06-24

Related Papers

Real-World Effectiveness and Safety of Insulin Glargine 300 U/mL in Insulin-Naïve People with Type 2 Diabetes: the ATOS Study.

2022-05-0913 citations

Switching to insulin glargine 300 U/mL: Is duration of prior basal insulin therapy important?

2018-04-096 citations

The effect of concomitant DPPIVi use on glycaemic control and hypoglycaemia with insulin glargine 300 U/mL (Gla-300) versus insulin glargine 100 U/mL (Gla-100) in people with type 2 diabetes: A patient-level meta-analysis of EDITION 2 and 3.

2018-01-251 citations

INSULIN GLARGINE 300 U/ML IS ASSOCIATED WITH LESS WEIGHT GAIN WHILE MAINTAINING GLYCEMIC CONTROL AND LOW RISK OF HYPOGLYCEMIA COMPARED WITH INSULIN GLARGINE 100 U/ML IN AN AGING POPULATION WITH TYPE 2 DIABETES.

2017-11-0614 citations

Comparison of Insulin Glargine 300 Units/mL and 100 Units/mL in Adults With Type 1 Diabetes: Continuous Glucose Monitoring Profiles and Variability Using Morning or Evening Injections.

2017-01-2383 citations

Glycaemic control and hypoglycaemia with new insulin glargine 300 U/ml versus insulin glargine 100 U/ml in people with type 2 diabetes using basal insulin and oral antihyperglycaemic drugs: the EDITION 2 randomized 12-month trial including 6-month extension.

2015-09-1483 citations

New insulin glargine 300 units/mL versus glargine 100 units/mL in people with type 2 diabetes using basal and mealtime insulin: glucose control and hypoglycemia in a 6-month randomized controlled trial (EDITION 1).

2014-07-30222 citations

New Insulin Glargine Formulation Associated with Less Nocturnal Hypoglycemia

MD Conference Express2013-11-01